10x Science, a company developing artificial intelligence to revolutionize molecular-level protein analysis, has closed a $4.8 million seed funding round. Led by Initialized Capital, the investment will accelerate the company's mission to automate a critical bottleneck in drug development. The platform delivers molecular insights in minutes, a process that traditionally takes scientists months of manual work.
Modernizing a Foundational Scientific Process
Protein characterization is a fundamental step in creating biologic therapeutics, from cancer treatments to gene therapies. Every new drug must be analyzed to ensure it is safe, effective, and manufacturable before proceeding. This crucial work currently relies on outdated tools and manual interpretation of complex mass spectrometry data.
The pharmaceutical industry's focus on complex protein drugs has created a demand for characterization that exceeds available expertise. 10x Science addresses this challenge with its purpose-built AI that automates the analysis of vast datasets. The system identifies molecular structures and chemical changes, delivering comprehensive results with unprecedented speed.
A Team Forged at the Intersection of Disciplines
The company was founded by David Stephen Roberts, Andrew Reiter, and Vishnu Tejus in Nobel laureate Carolyn Bertozzi's Stanford University lab. Their shared frustration with the lack of adequate tools for their cancer research spurred the creation of 10x Science. The founders aim to build a bridge between the life sciences and the technology world.
The team's expertise uniquely positions them to tackle this challenge, combining deep scientific knowledge with advanced AI capabilities. CEO David Roberts noted that their team comes from both worlds, enabling them to build an AI with the scientific depth to reason like an expert. This fusion of skills allows them to create a system that can identify patterns across thousands of therapeutics.
Pioneering AI for Practical Characterization
While AI has made strides in predicting protein structures, 10x Science focuses on the characterization layer where drug development decisions are made. COO Andrew Reiter explained that interpreting actual experimental data from therapeutic molecules has remained a painfully manual process. The company's platform is the first to apply AI to this critical, hands-on stage of research.
A core feature of the platform is its "deep memory," allowing it to learn from every dataset it processes. Crucially for a regulated industry, every result is explainable and traceable, providing the auditable data required for FDA filings. This continuous learning model stands in stark contrast to legacy tools that approach each analysis from scratch.
Investor Confidence and a Vision for Molecular Intelligence
The oversubscribed seed round highlights strong investor confidence in the company's approach. Zoe Perret of lead investor Initialized Capital described the venture as an investment in the essential infrastructure of drug development. She emphasized that the founders are a uniquely credible team solving an expensive and critical problem for the industry.
Nobel Laureate Carolyn Bertozzi praised the company for closing the gap between data generation and actionable insight. The funding will be used to hire engineers and expand collaborations with pharmaceutical and biotech partners. Ultimately, 10x Science aims to build a foundational layer of molecular intelligence for all life sciences.
With its new funding and pioneering AI platform, 10x Science is poised to redefine the standards for protein characterization. By transforming a slow, manual process into an automated, intelligent workflow, the company is accelerating drug development and unlocking a deeper understanding of biology. This innovation promises far-reaching implications for medicine, research, and our fundamental knowledge of life's molecules.